XML 30 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9

License and Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

				Three months ended March 31,
Partner		Drug or Drug Candidate		2015				2014
AstraZeneca AB		MOVANTIKTM (NKTR-118) and MOVANTIKTM fixed-dose combination program (NKTR-119)		$	90,000			$	—
Roche		PEGASYS® and MIRCERA®			3,212				3,197
Amgen, Inc.		Neulasta®			1,250				1,250
Bayer Healthcare LLC		BAY41-6551 (Amikacin Inhale)			810				752
Baxter Healthcare		BAX 855 (Hemophilia)			109				337
Other					1,359				2,545
License, collaboration, and other revenue				$	96,740			$	8,081

X

- Details

Name:	us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 808

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

+ Details

Name:	us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration